Welcome to our dedicated page for BHG news (Ticker: BHG), a resource for investors and traders seeking the latest updates and insights on BHG stock.
The BHG news page on Stock Titan functions as a historical archive for announcements related to the business that evolved into NeueHealth, Inc. Company communications describe NeueHealth as a value-driven healthcare company that aligns the interests of health consumers, providers, and payors to support high-quality, coordinated care. Over time, these releases trace the shift from a publicly traded structure to a privately held company acquired by an affiliate of New Enterprise Associates (NEA).
Readers can review earnings releases in which NeueHealth reports financial results, discusses Adjusted EBITDA performance, and highlights metrics such as value-based consumers served and enablement services lives. These updates also describe the company’s activity across the ACA Marketplace, Medicare, Medicaid, and ACO REACH arrangements, and explain how its value-driven, consumer-centric care model is applied in these programs.
The archive also includes transaction announcements, such as the December 23, 2024 disclosure of a definitive merger agreement with an NEA affiliate and the October 2, 2025 announcement of the closing of that take-private transaction. Other items include corporate updates like the acquisition of the remaining equity interest in Centrum Health, described as one of NeueHealth’s value-driven clinic brands.
By following this news history, users can see how the company presented its strategy, care model, and financial progress, as well as the steps leading to the cessation of public trading and transition to private ownership. This makes the BHG news page a useful resource for understanding the company’s evolution, rather than a source of ongoing, real-time updates.
NeueHealth, Inc. (NYSE: NEUE), a value-driven healthcare company, has announced its plans to report Third Quarter 2024 financial results on Thursday, November 7, 2024. The results will be released before the financial markets open, followed by a conference call at 8:00 AM Eastern Time.
Participants wishing to join the call via telephone must pre-register through a provided link. Upon registration, they will receive instructions on how to access the call, including dial-in details. Alternatively, a webcast of the earnings call will be available on NeueHealth's Investor Relations page at investors.neuehealth.com.
The company recommends participants dial in at least 15 minutes before the call starts. A recording of the earnings call and presentation will be made available on NeueHealth's Investor Relations page after the event concludes.
NeueHealth (NYSE: NEUE) reported solid Q2 2024 results, delivering positive Adjusted EBITDA for the second consecutive quarter. The company reaffirmed its full-year Adjusted EBITDA guidance and expects to reach the high end of its guidance range for consumers served by year-end. Key metrics include:
- Revenue: $225,991,000 (Q2 2024) vs $297,982,000 (Q2 2023)
- Net Loss: $57,698,000 (Q2 2024) vs $88,627,000 (Q2 2023)
- Adjusted EBITDA: $3,962,000 (Q2 2024) vs $7,797,000 (Q2 2023)
For 2024, NeueHealth projects:
- Revenue: ~$950 million
- NeueCare Revenue: ~$320 million
- NeueSolutions Revenue: ~$640 million
- Adjusted EBITDA: $15-25 million
The company continues to focus on advancing its value-driven model and delivering high-quality, consumer-centric care across ACA Marketplace, Medicare, and Medicaid populations.
NeueHealth, Inc. (NYSE: NEUE), a value-driven healthcare company, has announced its Second Quarter 2024 earnings conference call scheduled for August 7, 2024. The company will release its financial results before the markets open, followed by a conference call at 8:00 AM Eastern Time. Participants are encouraged to pre-register for the call and dial in at least 15 minutes early. A webcast of the earnings call will be accessible via NeueHealth's Investor Relations page, and a recording of the call and presentation will be available afterward on the same platform.
NeueHealth has secured a term loan facility for up to $150 million with Hercules Capital, significantly strengthening its balance sheet. This financing aims to advance NeueHealth's differentiated care model and support the company's strategic priorities in 2024 and beyond. The loan will help NeueHealth deliver value-driven, consumer-centric care across the ACA Marketplace, Medicare, and Medicaid. Both companies expressed optimism about the partnership's potential to drive value for payors, providers, and consumers.
NeueHealth announced it received a non-compliance letter from the NYSE on June 12, 2024. This notice states that the company failed to meet the continued listing standards due to its average market capitalization falling below $50 million over a 30 trading-day period and a stockholders’ deficit. As of June 11, 2024, NeueHealth's average market capitalization was approximately $49.7 million. The company's preferred stock, valued at $920.4 million as of March 31, 2024, is excluded from this calculation. The company's operations remain unaffected, and it has 45 days to submit a compliance plan to the NYSE. Pending NYSE's acceptance, the company has an 18-month period to regain compliance. During this period, NeueHealth will continue to trade under the symbol 'NEUE' with a '.BC' designation.
NeueHealth, Inc. reported strong Q1 '24 results with Revenue of $245.1 million, Net Income of $5.7 million, and Adjusted EBITDA of $2.5 million. They focus on consumer-centric care, provider partnerships, and consumer engagement. Revenue guidance for 2024 is around $1 billion, with expected segment revenues of $310-320 million for NeueCare and $690-700 million for NeueSolutions. The company aims for an Adjusted EBITDA of $15-25 million in 2024.
